215 related articles for article (PubMed ID: 29903916)
1. Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.
Tognon CE; Rafn B; Cetinbas NM; Kamura T; Trigo G; Rotblat B; Okumura F; Matsumoto M; Chow C; Davare M; Pollak M; Mayor T; Sorensen PH
J Biol Chem; 2018 Aug; 293(32):12502-12515. PubMed ID: 29903916
[TBL] [Abstract][Full Text] [Related]
2. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.
Tognon CE; Martin MJ; Moradian A; Trigo G; Rotblat B; Cheng SW; Pollard M; Uy E; Chow C; Carboni JM; Gottardis MM; Pollak M; Morin GB; Sorensen PH
Oncogene; 2012 Mar; 31(10):1334-40. PubMed ID: 21804605
[TBL] [Abstract][Full Text] [Related]
3. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
[TBL] [Abstract][Full Text] [Related]
4. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation.
Morrison KB; Tognon CE; Garnett MJ; Deal C; Sorensen PH
Oncogene; 2002 Aug; 21(37):5684-95. PubMed ID: 12173038
[TBL] [Abstract][Full Text] [Related]
5. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.
Martin MJ; Melnyk N; Pollard M; Bowden M; Leong H; Podor TJ; Gleave M; Sorensen PH
Mol Cell Biol; 2006 Mar; 26(5):1754-69. PubMed ID: 16478996
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway.
Werner H; Meisel-Sharon S; Bruchim I
Mol Cancer; 2018 Feb; 17(1):28. PubMed ID: 29455671
[TBL] [Abstract][Full Text] [Related]
7. A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.
Lannon CL; Martin MJ; Tognon CE; Jin W; Kim SJ; Sorensen PH
J Biol Chem; 2004 Feb; 279(8):6225-34. PubMed ID: 14668342
[TBL] [Abstract][Full Text] [Related]
8. The proximity-labeling technique BioID identifies sorting nexin 6 as a member of the insulin-like growth factor 1 (IGF1)-IGF1 receptor pathway.
Bareja A; Hodgkinson CP; Soderblom E; Waitt G; Dzau VJ
J Biol Chem; 2018 Apr; 293(17):6449-6459. PubMed ID: 29530981
[TBL] [Abstract][Full Text] [Related]
9. Identification of the degradation determinants of insulin receptor substrate 1 for signaling cullin-RING E3 ubiquitin ligase 7-mediated ubiquitination.
Xu X; Keshwani M; Meyer K; Sarikas A; Taylor S; Pan ZQ
J Biol Chem; 2012 Nov; 287(48):40758-66. PubMed ID: 23045529
[TBL] [Abstract][Full Text] [Related]
10. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages.
Lannon CL; Sorensen PH
Semin Cancer Biol; 2005 Jun; 15(3):215-23. PubMed ID: 15826836
[TBL] [Abstract][Full Text] [Related]
11. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
12.
Panebianco F; Kelly LM; Liu P; Zhong S; Dacic S; Wang X; Singhi AD; Dhir R; Chiosea SI; Kuan SF; Bhargava R; Dabbs D; Trivedi S; Gandhi M; Diaz R; Wald AI; Carty SE; Ferris RL; Lee AV; Nikiforova MN; Nikiforov YE
Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2307-2312. PubMed ID: 28193878
[TBL] [Abstract][Full Text] [Related]
13. Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors.
Chen J; Nagle AM; Wang YF; Boone DN; Lee AV
J Biol Chem; 2018 Mar; 293(10):3700-3709. PubMed ID: 29330302
[TBL] [Abstract][Full Text] [Related]
14. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.
Jenkins CE; Shevchuk OO; Giambra V; Lam SH; Carboni JM; Gottardis MM; Holzenberger M; Pollak M; Humphries RK; Weng AP
Exp Hematol; 2012 Sep; 40(9):715-723.e6. PubMed ID: 22613471
[TBL] [Abstract][Full Text] [Related]
15. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
[TBL] [Abstract][Full Text] [Related]
17. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
Jin W; Yun C; Hobbie A; Martin MJ; Sorensen PH; Kim SJ
Cancer Res; 2007 Apr; 67(7):3192-200. PubMed ID: 17409427
[TBL] [Abstract][Full Text] [Related]
18. E3 ubiquitin ligase RNF123 targets lamin B1 and lamin-binding proteins.
Khanna R; Krishnamoorthy V; Parnaik VK
FEBS J; 2018 Jun; 285(12):2243-2262. PubMed ID: 29676528
[TBL] [Abstract][Full Text] [Related]
19. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
[TBL] [Abstract][Full Text] [Related]
20. Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds.
Chan JY; Hackel BJ; Yee D
Mol Cancer Ther; 2017 Jul; 16(7):1324-1334. PubMed ID: 28468775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
